Introduction
Tocilizumab is an anti-interleukin-6 (IL-6) receptor monoclonal antibody used in the management of rheumatoid arthritis.1 It is effective at decreasing disease activity and improving function, and is used as monotherapy or in combination with other disease-modifying anti-rheumatic drugs.1 However, tocilizumab increases the risk of serious infections,2,3 which can present atypically for patients on tocilizumab – such as having mild clinical features despite disseminated infection,4 or having disproportionately low or normal C-reactive protein (CRP).5 We present a previously unreported case ofStaphylococcus aureus subcapsular splenic abscess with associated empyema in the setting of recent commencement of tocilizumab therapy.